Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955666 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects
A Phase 1 study, sponsored by Provention Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03955666: Completed Phase 1 study, sponsored by Provention Bio.
NCT03955666 is a Phase 1 study that has completed, run by Provention Bio. The registered enrollment target is 16 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955666, a Phase 1 study, has completed, sponsored by Provention Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects
Primary Outcome
Assessment of safety and tolerability
Interventions
- BIOLOGICAL PRV-3279 or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-08-07 |
| Est. Completion | 2019-12-11 |
| Phase | Phase 1 |
What the finished NCT03955666 record still lists
NCT03955666 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which PRV-3279 or placebo is the first listed.
NCT03955666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955666 about?
NCT03955666 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects". This Phase 1b study will evaluate the safety of PRV-3279 in healthy adult subjects
What is the current status of trial NCT03955666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-08-07. Estimated completion is 2019-12-11.
What interventions are being tested in trial NCT03955666?
The interventions under investigation include: PRV-3279 or placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT03955666?
This trial is sponsored by Provention Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03955666's enrollment target sits among peer trials
16 1786th of 2000 higher than 203 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI